JAC Advance Access originally published online on November 28, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 51, 77-81
© 2003 The British Society for Antimicrobial Chemotherapy
A comparison of antibiotic regimens in the treatment of acute melioidosis in a mouse model
Departments of 1 Microbiology and Immunology and 2 Chemistry, James Cook University; 3 Department of Clinical Microbiology, QHPS, Townsville Hospital, Townsville, Queensland 4814, Australia
Received 26 February 2002; returned 28 June 2002; revised 5 August 2002; accepted 12 September 2002
Melioidosis is caused by the Gram-negative bacillus Burkholderia pseudomallei. Most clinical reports of disease are from south-east Asia and northern Australia. The organism is intrinsically resistant to most commonly available antibiotics. Standard therapy includes ceftazidime either alone or in combination with co-trimoxazole. The clinical advantage in adding co-trimoxazole has never been determined; nor has the activity of newer, fourth-generation cephalosporins, such as cefepime, been studied in the treatment of this condition. BALB/c mice have been shown to represent an animal model of melioidosis. This animal model was used in this study to compare the efficacy of ceftazidime and cefepime alone or with co-trimoxazole, in the therapy of melioidosis. Antibiotic levels in the mice were determined by HPLC, and dosing was modified to keep plasma antibiotic levels at or above the MIC for the organism–antibiotic combination for a significant part of a 12 h period. Bacterial load, as determined by splenic counts, showed that ceftazidime in combination with co-trimoxazole was the most effective therapeutic option. The animal model described in this study can be used as a preliminary evaluation of therapeutic options for melioidosis.
* Corresponding author. Tel: +61-7-47961111; Fax: +61-7-47962415; E-mail: Robert_Norton{at}health.qld.gov.au
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Buijs, A. S. M. Dofferhoff, J. W. Mouton, and J. W. M. van der Meer Continuous administration of PBP-2- and PBP-3-specific {beta}-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis J. Antimicrob. Chemother., May 1, 2007; 59(5): 926 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Cheng and B. J. Currie Melioidosis: Epidemiology, Pathophysiology, and Management Clin. Microbiol. Rev., April 1, 2005; 18(2): 383 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. J. Inglis, F. Rodrigues, P. Rigby, R. Norton, and B. J. Currie Comparison of the Susceptibilities of Burkholderia pseudomallei to Meropenem and Ceftazidime by Conventional and Intracellular Methods Antimicrob. Agents Chemother., August 1, 2004; 48(8): 2999 - 3005. [Abstract] [Full Text] [PDF]
|
|